Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/214560
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis |
Autor: | Rodríguez-Lago, Iago; Sempere, Laura; Gutiérrez, Ana; Núñez Ortiz, Andrea; Leo Carnerero, Eduardo; Hinojosa, Esther; Mora, María; Cañete, Fiorella; Mañosa, Miriam; Herrera, Claudia; Beltrán, Belén; Forés, Ana; Arjona, Dolores; Barreiro-de Acosta, M.; Khorrami, Sam; Aguirre, Urko; Ginard, Daniel; Cabriada, José Luis | Palabras clave: | Ulcerative colitis Anti-TNF agents Loss of response Granulocyte–monocyte apheresis |
Fecha de publicación: | 2019 | Editor: | Taylor & Francis | Citación: | Scandinavian Journal of Gastroenterology 54(4): 459-464 (2019) | Resumen: | [Objective] To evaluate the effectiveness and safety of the combination of granulocyte–monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC). [Materials and methods] A retrospective, multicenter study was performed in 11 inflammatory bowel disease (IBD) Units. Clinical remission was defined as a partial Mayo score ≤2. The effectiveness of the treatment was evaluated by the partial Mayo score and the rate of anti-TNF intensification, switch, swap or colectomy. [Results] Forty-seven patients with ulcerative colitis were included (mean age 35 years, mean disease duration 52 months, 66% male and 59% extensive colitis). Twenty-three subjects were receiving infliximab, eighteen adalimumab and six golimumab. GMA was combined after a primary non-response (49%) or secondary loss of response (51%) to anti-TNF therapy. We observed a significant decrease in partial Mayo score and fecal calprotectin after GMA. Fifteen patients (32%) responded to the combination therapy without anti-TNF intensification, switch, swap or colectomy. Eight patients (17%) underwent colectomy. Two patients (4%) presented adverse events related to the technique. [Conclusions] Combination of GMA and anti-tumor necrosis factor is a safe and effective treatment after the loss of response to these biologic agents, with a significant decrease of the clinical disease activity and biomarkers, in a population with limited therapeutic alternatives. |
Versión del editor: | http://dx.doi.org/10.1080/00365521.2019.1600715 | URI: | http://hdl.handle.net/10261/214560 | DOI: | 10.1080/00365521.2019.1600715 | Identificadores: | doi: 10.1080/00365521.2019.1600715 issn: 0036-5521 e-issn: 1502-7708 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
14
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
11
checked on 22-feb-2024
Page view(s)
120
checked on 24-abr-2024
Download(s)
27
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.